Could a daily mushroom help shield aging brains?

NCT ID NCT07775833

Recruiting now Prevention Sponsor: National University of Singapore Source: ClinicalTrials.gov ↗

This trial is taking on new participants right now.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether taking golden oyster mushroom powder every day for two years can help preserve memory and thinking in middle-aged and older adults who are at higher risk for dementia. Around 600 community-living adults aged 45 to 80, who have a family history of dementia or notice their own memory slipping, will take either the mushroom powder or a placebo. Researchers will track changes in cognitive tests and blood markers to see if this simple dietary addition might offer brain protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Golden oyster mushroom powder (Pleurotus citrinopileatus) containing ergothioneine
What this could lead to: If effective, this could point toward a simple dietary supplement to help preserve memory and thinking in people at higher risk for dementia.
What could go wrong: This is an early-stage trial, and results may not show a clear benefit. Daily mushroom powder for 24 months may be hard for some to stick with, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * (1) Community-living adult aged 45 years to 80 years, AND * (2) Family history of Alzheimer's disease or having subjective cognitive (SCD) defined as "self-reported memory problems that have been getting worse over the past year.", AND * (3) Consume mushrooms no more than once a week, AND * (4) No dementia: CDR global score equal to zero. Exclusion Criteria: * (1) Any diagnosis of neurological diseases (e.g., epilepsy, stroke) made by a clinician, OR * (2) Any diagnosis of psychiatric illnesses (e.g., depressive disorders) made by a clinician, OR * (3) Significant sensory or motor impairments, OR * (4) Known allergy to mushrooms or a history of serious food allergies, OR * (5) Participants with a history of gout, OR * (6) Diagnosed with hyperuricemia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE ASSESSMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cognitive disorder dementia subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COGNITIVE ASSESSMENT DEMENTIA

Contacts and locations

Locations

Tahir Foundation Building, MD1, Level 12 (12 Science Drive 2)
RECRUITING

Singapore, 117549, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.